Medical News / From ASH Meeting 2019, Navitoclax/Ruxolitinib Combination Improves Outcomes for Patients With Myelofibrosis

Adding the novel small molecule inhibitor navitoclax to ongoing treatment with standard of care ruxolitinib (Jakafi) resulted in clinically meaningful reduction in spleen size and improvements in symptoms for patients with primary or secondary myelofibrosis, including those with resistance to ruxolitinib alone, according to findings from a phase II study presented at the 2019 ASH Annual Meeting. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Beaumont Health’s 29th Annual Cardiovascular Conference in Beaver Creek, CO, this February built on its own ... read more
The 29th Annual Beaumont Health Cardiovascular Conference, held in Beaver Creek, CO, provided cardiology investigators and ... read more
Despite the progress made in the fight against cardiovascular disease in recent decades, stroke and mitigating ... read more
There may soon be a cure for sickle cell disease. A team of investigators, led by Erica ... read more